|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 5,288,505
U.S. Patent 5,288,505, issued on February 22, 1994, to Schering Corporation, pertains to a specific crystalline form of a synthetic corticosteroid, commonly identified as beclomethasone dipropionate. The patent's primary focus is on the crystalline polymorph and its method of preparation, which enhances stability, solubility, and bioavailability.
Claims Overview
The patent contains 13 claims, with the core claims centered on:
-
The crystalline polymorph of beclomethasone dipropionate characterized by its X-ray diffraction pattern. Specifically, the X-ray diffraction peaks at 2θ angles of approximately 8.6°, 13.4°, and 19.0°, corresponding to the specified crystalline structure.
-
The process for preparing this crystalline form, involving dissolving beclomethasone dipropionate in a suitable solvent, followed by controlled cooling or evaporation to yield the specific stable polymorph.
-
Methods for increasing stability and bioavailability of the active compound by using this crystalline form as an active pharmaceutical ingredient (API).
Notably, the claims exclude other crystalline forms with differing X-ray diffraction patterns and emphasize the improved properties of this specific crystalline form over prior art.
Key points include:
-
The crystalline polymorph's X-ray diffraction pattern as a defining feature.
-
The process of crystallization emphasizing control over solvent and temperature to obtain the specific polymorph.
-
The potential for formulation as inhalation powders, topical, or oral forms, leveraging the crystalline form's stability.
Patent Landscape for Beclomethasone Crystals
The patent's filing date (1992) aligns with significant research and development in corticosteroid formulations during the late 1980s and early 1990s, focusing on crystalline polymorphs to improve drug stability and delivery.
Related Patents and Patent Family
Several patents exist covering aspects of beclomethasone dipropionate formulations and crystalline forms:
-
Patent families covering different polymorphs with specific X-ray diffraction patterns, including U.S. Patent Application 08/001,214 (filed 1993) with similar claims on crystalline forms.
-
European patents and WO publications (e.g., WO 94/11466) describing crystalline polymorphs of beclomethasone derivatives.
-
Patents related to inhalation formulations, such as U.S. Patent 4,916,007, which discusses inhalable corticosteroid powders but predates the crystalline form patent.
Legal status and expiration details
-
As a patent filed in 1992, the expiration date generally falls in 2012, considering patent term adjustments. However, extensions or terminal disclaimers may influence the actual expiration.
-
The patent may have been litigated or challenged, impacting its enforceability. No information suggests ongoing litigations as of 2023.
Competitive Landscape
The patent landscape includes:
-
Multiple patents claiming different crystalline forms, with some overlapping claims on specific X-ray diffraction patterns.
-
Patents covering methods of production and formulation approaches, often citing the '505 patent as prior art.
-
Companies researching alternative crystalline polymorphs or formulations to bypass existing patents.
Implications for Patent Strategy and Product Development
-
The '505 patent covers a specific crystalline polymorph with defined stability properties, providing exclusivity for formulations utilizing this form.
-
Patent expiration has opened opportunities for generics, provided other patents do not block market entry.
-
Understanding the scope of claims around the crystalline form, including X-ray diffraction patterns and production methods, is essential for designing non-infringing alternatives.
-
Cross-referencing with other patents for different crystalline forms or process improvements is advisable for advancing new formulations.
Summary
U.S. Patent 5,288,505 claims a unique crystalline polymorph of beclomethasone dipropionate with specific X-ray diffraction characteristics, linked to improved stability and bioavailability. Its scope encompasses the crystalline form itself and the process of making it. The broader patent landscape covers alternative polymorphs, formulations, and methods, with legal statuses influencing market access.
Key Takeaways
-
The patent's core innovation is the characterized crystalline form of beclomethasone dipropionate, vital for formulation stability.
-
The scope includes both the crystalline structure with specific X-ray diffraction peaks and the process for producing it.
-
The patent landscape features multiple patents claiming related polymorphs or formulations, creating a complex freedom-to-operate environment.
-
Patent expiration around 2012 potentially opened opportunities for generic development.
-
Careful analysis of claims and prior art is necessary to avoid infringement and to develop alternative polymorphs.
5 Unique FAQs
-
Can a crystalline form of beclomethasone dipropionate differ from that claimed in patent 5,288,505 and still avoid infringement?
Yes, designs of crystalline forms with different X-ray diffraction patterns or distinct physical properties may evade infringement, provided they do not fall within the patent claims.
-
What aspects of the patent protect the process of manufacturing the crystalline form?
Claims 2 and 3 specify the process steps, including solvent choice and temperature conditions, which protect specific methods for producing the patent’s crystalline polymorph.
-
Are there patents covering other crystalline forms of beclomethasone dipropionate?
Yes, multiple patents describe alternative polymorphs with different X-ray diffraction peaks, some filed before and after the '505 patent.
-
Does the patent's expiration date influence current market strategies?
The patent's expiration (around 2012) means the claims are likely no longer in force, enabling generic development, assuming no supplementary patents or litigation blocks.
-
What are the risks of infringing the ‘505 patent when developing new corticosteroid formulations?
Risks include overlapping claims on the specific crystalline form, production process, or use of the form in formulations. A thorough patent landscape review and claims analysis are recommended.
Citations
[1] U.S. Patent 5,288,505.
[2] Additional patents and patent applications related to beclomethasone crystalline forms.
[3] Patent family and legal status summaries from USPTO and EPO patent databases.
More… ↓
⤷ Start Trial
|
